Should We Change the Therapeutic Algorithm of Type 2 Diabetes Based on Accumulating Evidence?

Authors

  • Mona M. Salem

  • Dina O Abdulazim

Keywords:

type 1 diabetes; type 2 diabetes; micro-vascular complications; macrovascular complications; DPP4Is, SGLT2Is; nrf2 agonists

Abstract

In the last two decades, a dramatic shift in the paradigm of management of type 2 diabetes has been settled. Reduction of diabetic complications became the primary target instead of focusing on the mere glycemic control. The tight blood sugar control among type 1 (T1DM) and type 2 (T2DM) diabetes mellitus patients aimed at avoidance of long- term complications of diabetes. In spite of the significant impact of this approach on the incidence of these complications, the outcome is still not satisfactory. The frequent failure to achieve tight blood sugar control and the lack of hypoglycemic agents that are capable to combat the underlying pathogenic mechanisms of diabetic complications underlie this unsatisfactory outcome. These drawbacks are overcome in the newly introduced hypoglycemic agents. In this review, we are going to discuss these mechanisms and highlight the therapeutic value of the early use of these agents instead of the long-standing traditional approach.

How to Cite

Should We Change the Therapeutic Algorithm of Type 2 Diabetes Based on Accumulating Evidence?. (2019). Global Journal of Medical Research, 19(23), 27-47. https://medicalresearchjournal.org/index.php/GJMR/article/view/1796

References

Satija Hu F B (2015) Curbing the Diabetes Pandemic. 313(23), 2319.

(2016) Diabetes Mellitus - epidemiology.

Ingelfinger R, Rosen J (2019) Clinical Credence- SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease.

Rao Kondapally Seshasai, S. Kaptoge, S. Thompson, A., Di Angelantonio, E. Gao, P. Sarwar, N. (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. 364(9), 829-841.

Lidia Loukine, Chris Waters, Bernard Choi, Joellyn Ellison (2012) Loukine L, Waters C, Choi B C, Ellison J. Impact of diabetes mellitus on life expectancy and healthadjusted life expectancy in Canada. 10(1), 7. https://doi.org/10.1186/1478-7954-10-7

Y. Zheng, M. He, N. Congdon (2012) Zheng Y, He M, Congdon N The worldwide epidemic of diabetic retinopathy. 60(5), 428-431.

Schootman M (2008) Epidemiology of diabetes and diabetes-related complications Phys Ther. 88(11), 1254-1264.

Candrilli D, Davis L, Kan J, Lucero A, Rousculp D (2007) Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy J Diabetes Complications. 21(5), 306-314.

Humphry L, Ballard J, Frohnert P, Chu P, O'Fallon M, Palumbo J (1989) Chronic renal failure in non-insulin dependent diabetes mellitus. A population-based study in Rochester, Minnesota. 111, 788-796.

R. DeFronzo (1995) Diabetic nephropathy: etiologic and therapeutic considerations. 3, 510-564.

Nichols A, Hillier A, Erbey R, Brown B (2001) Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors Diabetes Care. 24(9), 1614-1619.

Melec Zeadin, Christina Petlura, Geoff Werstuck (2013) Molecular Mechanisms Linking Diabetes to the Accelerated Development of Atherosclerosis. 37(5), 345-350. https://doi.org/10.1016/j.jcjd.2013.06.001

Chen R, Ovbiagele B, Feng W (2016) Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes Am J Med Sci. 351(4), 380-386.

Milton Packer (2017) Activation and Inhibition of Sodium- Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus with That of Heart Failure Circulation. 136(16), 1548-1559. https://doi.org/10.1161/circulationaha.117.030418

Kenneth Maiese, New (2015) Maiese K New Insights for Oxidative Stress and Diabetes Mellitus. 2015, 1-17. https://doi.org/10.1155/2015/875961

Cai W, Duan M, Liu Y, Yu J, Tang L, Liu L (2017) Uric Acid Induces Endothelial Dysfunction by Activating the HMGB1/RAGE Signaling Pathway. 2017, 4391920. https://doi.org/10.1155/2017/4391920

F. Whaley, J. (2011) Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.

(1993) The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. 329(14), 977-986. https://doi.org/10.1056/nejm199309303291401

UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). 352(9131), 837-853. https://doi.org/10.1016/s0140-6736(98)07019-6

Ray K, Wijesuriya Seshasai S R, Nethercott Sivakumaran R, et Preiss D (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. 373, 1765-1772.

UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 352(9131), 854-865. https://doi.org/10.1016/s0140-6736(98)07037-8

(2018) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2018 Executive Summary. 24(1), 91-120.

Røder E (2018) Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential Ther Adv Chronic Dis. 9(1), 33-50.

Solis-Herrera Triplitt C, Cersosimo E, Abdul- M, Defronzo mpagliflozin (2015) mpagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. 16(18), 2819-33.

Wakisaka M, Nagao T (2017) Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy.

Furchgott F, Zawadzki V (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine Nature. 288, 373-376.

Roy D, Perreault M, Marette A (1998) Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. 274(4 Pt 1), 692-9.

Wang H, Wang X, Barrett J (2011) Caveolin-1 is required for vascular endothelial insulin uptake. 300(1), E134-E144.

Kolka M, Bergman N (2013) The endothelium in diabetes: its role in insulin access and diabetic complications Rev Endocr Metab Disord. 14(1), 13-19.

Shenouda M, Chen Widlansky M E, Holbrook Xu G, et Tabit C E (2011) Altered Mitochondrial Dynamics Contributes to Endothelial Dysfunction in Diabetes Mellitus. 124(4), 444-453.

Sharma A, Bernatchez N, de B (2012) Targeting endothelial dysfunction in vascular complications associated with diabetes. 2012. https://doi.org/10.1155/2012/750126

Ganley-Leal Farb M G, Liang Mott M, Ercan B, et Widlansky M E (2011) Arteriolar Function in Visceral Adipose Tissue Is Impaired in Human Obesity. 32(2), 467-473.

Jia Liu, Linda Jahn, Dale Fowler, Eugene Barrett, Wenhong Cao, Zhenqi Liu (2011) Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans J Clin Endocrinol Metab. 96(2), 438-446. https://doi.org/10.1210/jc.2010-1174

Li Rask-Madsen C, Feather Freund B, Wu Abramov R, et al (2010) Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. 11(5), 379-389.

Tremolada G, Del C, Lattanzio R, Maestroni S, Maestroni A, Bandello F (2012) The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment. 2012, 1-8. https://doi.org/10.1155/2012/728325

Simon Satchell (2012) The glomerular endothelium emerges as a key player in diabetic nephropathy Kidney Int. 82(9), 949-951. https://doi.org/10.1038/ki.2012.258

Alin Stirban (2014) Stirban A Microvascular dysfunction in the context of diabetic neuropathy. 14(11), 541. https://doi.org/10.1007/s11892-014-0541-x

L. Exalto, R. Whitmer, L. Kappele, G. Biessels (2012) An update on type 2 diabetes, vascular dementia and Alzheimer's disease Exp Gerontol. 47(11), 858-864. https://doi.org/10.1016/j.exger.2012.07.014

Yukiko Kanetsuna, Keiko Takahashi, Michio Nagata, Maureen Gannon, Matthew Breyer, Raymond Harris, Takamune Takahashi (2007) Deficiency of Endothelial Nitric-Oxide Synthase Confers Susceptibility to Diabetic Nephropathy in Nephropathy-Resistant Inbred Mice. 170(5), 1473-1484. https://doi.org/10.2353/ajpath.2007.060481

Wang Zhao H J, Cheng H, Takahashi Zhang M Z, et Fogo A B (2006) Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. 17, 2664-2669.

Bentzien Huber J D, Burke Boyer S J, Eickmeier De Lombaert S, et al (2012) Identification of a Potent Sodium Hydrogen Exchanger Isoform 1 (NHE1) Inhibitor with a Suitable Profile for Chronic Dosing and Demonstrated Cardioprotective Effects in a Preclinical Model of Myocardial Infarction in the Rat. 55(16), 7114-7140.

Tsapas Sarigianni M, Kaloyianni Mikhailidis D P, Fliegel Koliakos G, et al (2010) Na + /H + exchanger-1: a link with atherogenesis?. 19(12), 1545-1556.

S. Wang, Q. Peng, J. Zhang, L. Liu (2008) Na+/H+ exchanger is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain Cardiovasc Res. 80(2), 255-262.

Milton Packer (2017) Activation and Inhibition of Sodium- Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus with that of Heart Failure Circulation. 136(16), 1548-1559. https://doi.org/10.1161/circulationaha.117.030418

Katusic S, Austin A (2016) Neurovascular Protective Function of Endothelial Nitric Oxide - Recent Advances Circ J. 80(7), 1499-1503.

Alves-Lopes R, Neves B, Montezano C, Harvey A, Carneiro S, Touyz M (2016) Internal pudental artery dysfunction in diabetes mellitus is mediated by NOX1-derived ROS-, Nrf2-, and Rho kinasedependent mechanisms Hypertension. 68, 1056-1064.

Liu Yang S, Yang Ge B (2013) Protective effects of cariporide on endothelial dysfunction induced by homocysteine Pharmacology. 92(5-6), 303-309.

Packer M (2017) Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. 20.

Gao Chang H B, Hu Nepomuceno R, paradoxical cariporide (2015) Na+/H+ exchanger in the regulation of platelet activation and paradoxical effects of cariporide. 272, 11-16.

Osar Z, Samanci T, Demirel Y, Damci T, Ilkova H (2004) Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus Exp Diabesity Res. 5(2), 155-162.

Hansen S, Aasum E, Hafstad D (2017) The role of NADPH oxidases in diabetic cardiomyopathy.

Roy S, Kim D, Hernandez C, Simo R, Roy S (2015) Beneficial effects of fenofibric acid on over expression of extracellular matrix components, cox- 2, and impairment of endothelial permeability associated with diabetic retinopathy. 140, 124-9.

Othman A, Ahmad S, Megyerdi S (2013) Lipoxygenasederived lipid metabolites induce retinal endothelial cell barrier dysfunction: Contribution of NADPH oxidase. 8(2), e57254. https://doi.org/10.1371/journal.pone.0057254

Wada J, Makino H (2013) Inflammation and the pathogenesis of diabetic nephropathy Clin Sci (Lond). 124(3), 139-152.

Bingmei Yang, Andrea Hodgkinson, Peter Oates, Beverley Millward, Andrew Demaine (2008) High glucose induction of DNAbinding activity of the transcription factor NF-κB in patients with diabetic nephropathy Biochim Biophys. 1782(5), 295-302. https://doi.org/10.1016/j.bbadis.2008.01.009

Yu Ha H, Kitamura Choi Y J, Lee B (2002) Role of high glucose-induced nuclear factor-κB activation in monocyte chemo attractant protein-1 expression by mesangial cells. 13, 894-902.

Park W, Kim H, Lee H, Kim S, Ahn J, et Shin Y S (2000) High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-ϰB-dependent. 43, 1544-1553.

Kashihara N, Haruna Y, Kondeti K, Kanwar S (2010) Oxidative Stress in Diabetic Nephropathy. 17, 4256-4269.

D. Jalal, C. Rivard, R. Johnson, D. Maahs, K. McFann, M. Rewers, J. Snell-Bergeon (2010) Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study Nephrol Dial Transplant. 25(6), 1865-1869.

Ficociello H, Rosolowsky T, Niewczas A, Maselli J, Weinberg M, Aschengrau A, Eckfeldt H, Stanton C, Galecki T, Doria A, Warram H, Krolewski S (2010) High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up Diabetes Care. 33(6), 1337-1343.

Hovind P, Rossing P, Tarnow L, Johnson J, Parving H (2009) Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study Diabetes. 58(7), 1668-1671.

Dandan Yan, Yinfang Tu, Feng Jiang, Jie Wang, Rong Zhang, Xue Sun, Tao Wang, Shiyun Wang, Yuqian Bao, Cheng Hu, Weiping Jia (2015) Yan D, Tu Y, Jiang F, Wang J, Zhang R, Sun X, Wang T, Wang S, Bao Y, Hu C, Jia W Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population. 10(6), e0129797. https://doi.org/10.1371/journal.pone.0129797

Viazzi De Cosmo S, Giorda Pacilli A, Gentile Ceriello A, Russo G, Nicolucci Rossi M C, Feig Guida P, Johnson J, Pontremoli R; AMD-Annals Study Group (2015) Serum Uric Acid and Risk of CKD in Type 2 Diabetes Clin J Am Soc Nephrol. 10(11).

Takae K, Nagata M, Hata J, Mukai N, Hirakawa Y, Yoshida D, Kishimoto H, Tsuruya K, Kitazono T, Kiyohara Y, Ninomiya T (2016) Serum Uric Acid as a Risk Factor for Chronic Kidney Disease in a Japanese Community - The Hisayama Study Circ J. 80(8), 1857-1862.

Bartáková V, Kuricová K, Pácal L, Nová Z, Dvořáková V, Švrčková M (2016) Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus. 30(7), 1300-1307. https://doi.org/10.1016/j.jdiacomp.2016.06.002

Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y (2015) Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallelcontrolled study.Clin Endocrinol (Oxf). 83(4), 475-482.

Tahir Kanji, Mandark Gandhi, Catherine Clase, Robert Yang (2015) Kanji T, Gandhi M, Clase C M, Yang R Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. 16(1), 58. https://doi.org/10.1186/s12882-015-0047-z

Erlandsson Harris, H. Andersson, U. (2004) Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator Eur J Immunol. 34(6), 1503-1512.

Ji Wang, Tianqiang Qin, Jianrong Chen, Yulin Li, Ling Wang, He Huang, Jing Li (2014) Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. 9(12), e114259. https://doi.org/10.1371/journal.pone.0114259

T. Vilsbøll, J. Holst (2004) Incretins, insulin secretion and type 2 diabetes mellitus Diabetologia. 47(3), 357-366. https://doi.org/10.1007/s00125-004-1342-6

Kalra S (2013) Glucagon-like peptide-1 receptors agonists (GLP1 RA). 63(10), 1312-5.

S. Ross, J. Ekoé (2010) Incretin agents in type 2 diabetes Can Fam Physician. 56(7), 639-648.

Inzucchi E, Bergenstal M, Buse B, Diamant M, Ferrannini E, Nauck M (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patientcentered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care. 38(1), 140-149. https://doi.org/10.2337/dc14-2441

Jacob Sivertsen, Jaya Rosenmeier, Jens Holst, Tina Vilsbøll (2012) The effect of glucagon-like peptide 1 on cardiovascular risk. 9(4), 209-222. https://doi.org/10.1038/nrcardio.2011.211

Daniel Drucker (2016) The Cardiovascular Biology of Glucagon-like Peptide-1. 24(1), 15-30. https://doi.org/10.1016/j.cmet.2016.06.009

Olson Lepore J J, Demopoulos L, Barbour M (2016) Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. 4(7), 559-566. https://doi.org/10.1016/j.jchf.2016.01.008

Margulies B, Hernandez F, Redfield M, Givertz M, Oliveira H, Cole R (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. 316(5), 500. https://doi.org/10.1001/jama.2016.10260

Pfeffer A, Claggett B, Diaz R, Dickstein K, Gerstein C, Køber V (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. 373(23), 2247-2257. https://doi.org/10.1056/nejmoa1509225

Marso P, Daniels H, Brown-Frandsen K, Kristensen P, Mann F, Nauck A (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. 375(4), 311-322. https://doi.org/10.1056/nejmoa1603827

Marso P, Bain C, Consoli A, Eliaschewitz G, Jódar E, Leiter A (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. 375(19), 1834-1844. https://doi.org/10.1056/nejmoa1607141

Holman R R, M. Bethel, R. Mentz, V. Thompson, Y. Lokhnygina, J. Buse (2017) Effects of onceweekly exenatide on cardiovascular outcomes in type 2 diabetes N Engl J Med. 377(13), 1228-1239.

Keith Ferdinand, Fady Botros, Charles Atisso, Philip Sager (2016) Ferdinand K C, Botros F T, Atisso C M, Sager P T Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. 15(1), 38. https://doi.org/10.1186/s12933-016-0355-z

Thomas C. (2017) The potential and pitfalls of GLP- 1 receptor agonists for renal protection in type 2 diabetes. 43(Suppl 1), 20-2.

J. Int (2016) Aroor A, Zuberek M, Duta C, Meuth A, Sowers J R, Whaley-Connell A, et al., Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules. (5), 780.

Girardi C, Fukuda E, Rossoni V, Malnic G, Reboucas A (2008) Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. 294, F414-F422.

Marcel Muskiet, Mark Smits, Linde Morsink, Michaela Diamant (2014) The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?. 10(2), 88-103. https://doi.org/10.1038/nrneph.2013.272

Scirica M, Braunwald Bhatt D L, Davidson Steg P G, et Hirshberg B, Saxagliptin (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. 369, 1317-1326.

J. Udell, D. Bhatt, E. Braunwald, M. Cavender, O. Mosenzon, P. Steg (2015) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. 38, 696-705.

Eun Lee, J. Kim, J. Lee, M. Song, H. Ghee, J. Kang, Y. (2016) DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. 96(5), 547-560.

J. Am (2012) Glorie L L, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N, et al., DPP4 inhibition improves functional outcome after renal ischemiareperfusion injury.

J. Holst, C. Deacon (2005) Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. 48(4), 612-615. https://doi.org/10.1007/s00125-005-1705-7

J. Am (2017) Nistala R, Savin V Diabetes, hypertension and chronic kidney disease progression: Role of DPP4. (4), F661-F670.

Deacon F (2005) What do we know about the secretion and degradation of incretin hormones?. 128(2), 117-24.

M. De, I. Korom, S. Van, D. Scharpe, S. (1999) CD26, let it cut or cut it down. 20, 367-375.

Klemann C, Wagner L, Stephan M, von S (2016) Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. 185(1), 1-21. https://doi.org/10.1111/cei.12781

Famulla Lamers D, Hartwig Wronkowitz N, Lehr S, et Ouwens D M (2011) Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome. 60.

(2016) Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes. 2016, 7481470.

Eckel Röhrborn D, smooth Lett (2014) Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up‐regulated by hypoxia in human adipocytes and smooth muscle cells. 588(21), 3870-7.

Adriana Girardi, Brenda Degray, Tamas Nagy, Daniel Biemesderfer, Peter Aronson (2001) Association of Na+-H+ Exchanger Isoform NHE3 and Dipeptidyl Peptidase IV in the Renal Proximal Tubule. 276(49), 6671-4667. https://doi.org/10.1074/jbc.m106897200

J. Int (2016) Aroor A, Zuberek M, Duta C, Meuth A, Sowers JR, Whaley-Connell A, et al., Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules. (5), 780.

Michael Gekle (2005) RENAL TUBULE ALBUMIN TRANSPORT. 67(1), 573-594. https://doi.org/10.1146/annurev.physiol.67.031103.154845

G. Dekan, A. Miettinen, E. Schnabel, M. Farquhar (1990) Binding of monoclonal antibodies to glomerular endothelium, slit membranes, and epithelium after in vivo injection. Localization of antigens and bound IgGs by immunoelectron microscopy. 137, 913-927.

Alter L, Ott M, Tsuprykov von W K, Krause-Relle Sharkovska Y, et al (2012) DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. 36, 119-351.

Leibowitz Mosenzon O, Cahn Bhatt DL, Hirshberg B, Wei al (2017) Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. 40, 69-76.

Cornel H, Bakris L, Alvarsson Stevens S R, BaxW A, et Chuang L M (2016) Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. 39, 2304-2310.

White B, Cannon P, Heller R, Nissen E, Bergenstal M, et Bakris G L (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. 369, 1327-1335.

Groop H, Perkovic Cooper M E, Kanasaki Hocher B, et Haneda M, Linagliptin, its hyperglycaemia (2017) Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial. 19, 1610-1619.

Groop H, Perkovic Cooper M E, Emser A, Woerle J, renal dysfunction (2013) Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction. 36(11), 3460-3468.

Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y (2014) Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. 63 sx(6), 2120-31.

Shi S, Kanasaki Srivastava S P, Kitada He J, et Nagai T (2015) Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition. 88(3), 479-489.

Y. Kim, G 4, Hj Cho, H. Jeong, S. Lee, S. Lee (2016) Lee C S 1, 2, 3, Kim Y G 4, Cho HJ 1, 2, 4, Park J 1, 2, 4, Jeong H 1, Lee S E 1, 2, 4, Lee S P et al., Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation. 1, 29393.

Chung R, Park W, Kim W (2016) PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES. 36(12), 2357-2363.

Milton Packer (2018) Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. 17(1), 9. https://doi.org/10.1186/s12933-017-0648-x

V. Ferdousie, M. Mohammadi, G. Hassanshahi, H. Khorramdelazad, S. Falahati-Pour, M. Mirzaei (2017) Ferdousie V T, Mohammadi M M, Hassanshahi G, Khorramdelazad H, Falahati-Pour S K, Mirzaei M, et al., Serum CXCL10 and CXCL12 chemokine levels are associated with the severity of coronary artery disease and coronary artery occlusion. 233, 23-28.

J. Am (2011) Darisipudi M N, Kulkarni O P, Sayyed S G, Ryu M, Migliorini A, Sagrinati C, et al., Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. 179(1), 116-124. https://doi.org/10.1016/j.ajpath.2011.03.004

Butler M, Koc Guthrie S M, Caballero Afzal A, et Brooks H L, sufficient retinopathy (2005) SDF-1 is both necessary and sufficient to promote proliferative retinopathy. 115, 86-93.

Hompesch DeFronzo R A, Liu Kasichayanula S, Pfister Hong Y, et al (2013) Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes. 36, 3169-3176.

J. Clin (2017) van Bommel E J, Muskiet M H, Tonneijck L, Kramer M H, Nieuwdorp M, van Raalte D H SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. 12(4), 700-710.

Samukawa Chino Y, Nakai Sakai S, Nakanishi Yamaguchi J, et al (2014) SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. 35, 391-404.

Bjornstad P, Ishimoto Lanaspa M A, Kume Kosugi T, et Jalal D, Fructose, uric nephropathy (2015) Fructose and uric acid in diabetic nephropathy. 58(9).

M. García, F. García-Arroyo, E. Tapia, H. Osorio, A. Arellano-Buendía, M. Madero (2015) Cristóbal-García M, García-Arroyo F E, Tapia E, Osorio H, Arellano-Buendía A S, Madero M, et al., Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension. 2015, 535686.

Ryu E-S, Kim J, Shin H-S, Jang H, Choi S, Jo I (2013) Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. 304, 471-80.

Ding al (2015) Wuling San protects kidney dysfunction by inhibiting renal TLR4/MyD88 signaling and NLRP3 inflammasome activation in high fructose-induced hyperuricemic mice. 169, 49-59.

Leonard Hayflick (2003) Living forever and dying in the attempt. 38(11-12), 1231-1241. https://doi.org/10.1016/j.exger.2003.09.003

Nakano Kitada K, Hitomi Ohsaki H, Yatabe Minamino T, et al (2014) Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. 28(5), 604-611.

Panchapakesan U, Pegg K, Gross S, Komala G, Mudaliar H, Forbes J (2013) Effects of SGLT2 inhibition in human kidney proximal tubular cells-- renoprotection in diabetic nephropathy?. 8(2), e54442.

A. Ojima, T. Matsui, Y. Nishino, N. Nakamura, S. Yamagishi (2015) Empagliflozin, an Inhibitor of Sodium- Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis Horm Metab Res. 47(9), 686-692.

Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. 9(6), e100777. https://doi.org/10.1371/journal.pone.0100777

Cicerchi C, Li N, Kratzer J, Garcia G, Roncal- A, Tanabe K (2014) Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. 28(8), 3339-50.

Jph Wilding (2014) The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. 63, 1228-1237.

Wanner C, Inzucchi E, Fitchett Lachin J M, Mattheus von Eynatten M, Empagliflozin et al (2016) Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. 375(4), 323-334.

Brenner M, Cooper E, de D, Keane F, Mitch E, Remuzzi Parving H H, Zhang Snapinn S M, Shahinfar Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med. 345(12), 861-869.

Yamout H, Bakris L (2016) Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy Nat Rev Nephrol. 12(10), 583-584.

Thomas Grempler R, Himmelsbach Eckhardt M, Sauer A, et Sharp D E, Empagliflozin (2012) Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors. 14(1), 83-90.

Cherney Z, Soleymanlou Perkins B A, Lai Maione M, et Lee A (2014) Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus. 129(5), 587-597.

(2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. 61(3), 722-726.

Roberto Vettor, Silvio Inzucchi, Paola Fioretto (2017) The cardiovascular benefits of empagliflozin: SGLT2- dependent and -independent effects Diabetologia. 60(3), 395-398. https://doi.org/10.1007/s00125-016-4194-y

Baartscheer A, Schumacher A, Wüst C, Fiolet W, Coronel Stienen G J, et al, rabbits (2017) Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. 60(3), 568-573.

Skrtić M, Yang K, Soleymanlou Perkins B A, Lytvyn Y, et von Eynatten M, renal hyperfiltration (2014) Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. 57(12), 2599-2602.

Lambers Heerspink, H. de Zeeuw, D. Wie, L. Leslie, B. List, J. (2013) Dapagliflozin a glucoseregulating drug with diuretic properties in subjects with type 2 diabetes Diabetes Obes Metab. 15(9), 853-862.

Cherney Z, Soleymanlou Perkins B A, Zimpelmann Xiao F, et Woerle H J (2014) Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. 86(5), 1057-1058.

Heerspink J, Desai M, Jardine M, Balis D, Meininger G, Perkovic V (2017) Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects J Am Soc Nephrol. 28(1), 368-375.

Tang H, Li G, Zhao Y, Wang F, Gower W, Shi L (2018) Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network metaanalysis. 20(5), 1262-1279. https://doi.org/10.1111/dom.13232

Perkovic Neal B, Mahaffey W, Fulcher de Zeeuw D, Canagliflozin et al, Cardiovascular (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. 377(7), 644-657.

(2018) Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. 137(4), 323-334.

Raz Wiviott S D, Mosenzon Bonaca M P, et Kato E T, Dapagliflozin (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. 380(4), 347-357.

Rhm Furtado, M. Bonaca, I. Raz, T. Zelniker, O. Mosenzon (2019) Furtado RHM, Bonaca M P, Raz I, Zelniker T A, Mosenzon O. et al., Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Subanalysis from DECLARETIMI-58 Trial.

Das R, Everett M, Birtcher K, Brown M, et Cefalu W T (2018) 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. 72, 3200-3223.

Perkovic V, Jardine J, Neal B, Bompoint S, Heerspink HJL (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Mosenzon O, Wiviott D, Cahn A, Rozenberg A, Yanuv I (2019) Effects of dapagliflozin on development and progression of kidney diseasein patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. 7(8), 606-617. https://doi.org/10.1016/s2213-8587(19)30180-9

Di E, Sharma Jha J C, Wilkinson-Berka L, Jandeleit-Dahm A (2015) Are reactive oxygen species still the basis for diabetic complications?. 129(2), 199-216.

C. Zoja, A. Benigni, G. Remuzzi (2014) The Nrf2 pathway in the progression of renal disease. i19-i24.

Matzinger M, Fischhuber K, Heiss H (2017) Activation of Nrf2 signaling by natural products-can it all eviate diabetes?. 0734-9750.

Joshua David, William Rifkin, Piul Rabbani, Daniel Ceradini (2017) David J A, Rifkin W J, Rabbani P S, Ceradini DJThe Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus. 2017, 4826724. https://doi.org/10.1155/2017/4826724

Jiménez-Osorio S, González-Reyes S, Pedraza- J (2015) Natural Nrf2 activators in diabetes Clin Chim Acta. 448, 182-192.

J. Int (2016) Zhang X, He H, Liang D, Jiang Y, Liang W, Chi Z H, et al., Protective Effects of Berberine on Renal Injury in Streptozotocin (STZ)-Induced Diabetic Mice. (8).

Raish M, Ahmad A, Jan L, Alkharfy M, Ansari A, Mohsin K (2016) Momordica charantia polysaccharides mitigate the progression of STZ induced diabetic nephropathy in rats. 91, 394-9.

Yin Q, Xia Y, Wang G (2016) Sinomenine alleviates high glucose-induced renal glomerular endothelial hyperpermeability by inhibiting the activation of RhoA/ROCK signaling pathway Biochem Biophys Res Commun. 477(4), 881-886.

Bahadoran Z, Tohidi M, Nazeri P, Mehran M, Azizi F, Mirmiran P (2012) Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients: a randomized double-blind clinical trial Int J Food Sci Nutr. 63(7), 767-771.

J. Br (2011) Brasnyó P, Molnár G A, Mohás M, Markó L, Laczy B, Cseh J, et al., Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. 106(3), 383-389.

Goh P, Lee Y, Lau P, Supaat W, Chan H, Koh F (2014) Effects of resveratrol in patients with type 2 diabetes mellituson skeletal muscle SIRT1 expression and energy expenditure Int J Sport Nutr Exerc Metab. 24(1), 2-13.

J. Am (2016) Thazhath S S, Wu T, Bound M J, Checklin H L, Standfield S, Jones K L et al., Administration of resveratrol for 5 wk has no effect on glucagonlike peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. 103(1), 66-70.

J. Am (2012) Tomé-Carneiro J, Gonzálvez M, Larrosa M, Yáñez- Gascón M J, García-Almagro F J, Ruiz-Ros J A, et al., One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. 110(3), 356-363.

Larrosa Tomé-Carneiro J, Dávalos Yáñez-Gascón M J, Gonzálvez Gil-Zamorano J, et al (2013) One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. 72, 69-82.

Ponzo Bo S, Evangelista Ciccone G, Saba F, Goitre al (2016) Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. 111, 896-905.

R. Wong, R. Nealon, A. Scholey, P. Howe (2016) Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus. 26(5), 393-399.

Wong R H, D. Raederstorff, P. Howe (2016) Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus. (7), 425.

Yamaguchi Imamura H, Saiki Nagayama D, Shirai K (2017) Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus. 58(4), 577-583.

Usharani P, Mateen A, Naidu U, Raju S, Chandra N (2008) Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study Drugs R D. 9(4), 243-250.

Azad Javidnia K, Malekmakan L, et Nasab M H, transforming factor-β, double-blind, placebo-controlled Nephrol (2011) Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. 45(5), 365-70.

Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S (2012) Curcumin extract for prevention of type 2 diabetes Diabetes Care. 35(11), 2121-2127.

(2014) Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type 2 Diabetes. 27(11), 902-6.

R. Neerati P 1, Devde, A. Gangi (2014) Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus Phytother Res. 28(12), 1796-1800.

Na L X 1, Y. Li, H. Pan, X. Zhou, D. Sun, M. Meng, X. Li, C. Sun (2013) Curcuminoids exert glucoselowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebocontrolled trial. 57(9), 1569-77.

Alan Garber, Martin Abrahamson, Lawrence Joshua I. Barzilay, et al (2019) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2019 Executive Summary. 25(1), 69-100.

M. Turner (2003) The role of mannose-binding lectin in health and disease Mol Immunol. 40(7), 423-429.

Forsblom Saraheimo M, Hansen K, Fagerudd Teppo A M, et al, overt nephropathy (2005) Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. 48(1), 198-202.

Li Q, Chang Y, Chen M, Zhao H (2018) Complement activation in patients with diabetic nephropathy. 1262-3636.

Zhang Man X, Ma Yu H (2015) Increased serum mannose binding lectin levels are associated with diabetic retinopathy. 29(1), 55-58.

Huang Q, Shang G, Deng H, Liu J, Mei Y (2015) High Mannose-Binding Lectin Serum Levels Are Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes. 10(7), e0130665. https://doi.org/10.1371/journal.pone.0130665

Zhao Q, Hu Lectin (2016) Mannose‐Binding Lectin and Diabetic Nephropathy in Type 1 Diabetes. 30(4), 345-350.

Ling-Zhi Guan, Qiang Tong, Jing Xu (2015) Guan L Z, Tong Q, Xu J. Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes. 10(3), e0119699. https://doi.org/10.1371/journal.pone.0119699

Hansen K, Tarnow L, Thiel S, Steffensen R, Stehouwer D Association between mannose-binding lectin and vascular complications analysis. 13(12), e0208905.

American Diabetes Association (2016) Standards of medical care in diabetes-2016. 39(Suppl 1), S1-S109.

Holman R R, S. Paul, M. Bethel, D. Matthews, Haw Neil (2008) year follow-up of intensive glucose controlin type 2 diabetes N Engl J Med. 359, 1577-1589.

(1993) The course of kidney function in type 2 (non-insulindependent) diabetic patients with diabetic nephropathy Diabetologia. 36(10), 1071-1078.

Should we Change our Therapeutic Management of Type 2 Diabetes based on Accumulating Evidence?

Published

2019-07-01

How to Cite

Should We Change the Therapeutic Algorithm of Type 2 Diabetes Based on Accumulating Evidence?. (2019). Global Journal of Medical Research, 19(23), 27-47. https://medicalresearchjournal.org/index.php/GJMR/article/view/1796